The Conversation (0)
Neovasc released its financial result for the second quarter of 2017.
Neovasc (NASDAQ:NVCN; TSX:NVCN) released its financial result for the second quarter of 2017.
As quoted in the press release:
“For both the Tiara and Reducer, the quarter saw consistent progress across North America and Europe,” commented Neovasc CEO, Alexei Marko. “As we get closer to key decisions from the U.S. Court of Appeals, our regulatory and commercial teams are gaining momentum from both the clinical and commercial results our innovative cardiovascular products are producing.”
The Company’s proprietary product for treating mitral valve disease, the Tiara™ (“Tiara”), continues to perform well and has now been used to treat 33 patients under early feasibility, compassionate use and clinical study protocols across North America and Europe. The 30-day survival rate for those treated more than 30 days ago is 88%. The longest surviving patient treated with Tiara is now almost three and half years’ post implant. The Company added additional sites to its CE Mark trial during the quarter with UK approval, and is in the process of adding additional sites in Italy, Germany and the U.S.
Click here to read the full press release.
Source: www.newswire.ca
